Using advanced MRI to tell apart tumor recurrence from false alarms in brain cancer patients
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases- AiD GLIO Pilot Trial
This study is testing if a new type of MRI can help doctors tell the difference between real tumor growth and false alarms in patients with glioblastoma or brain metastases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT05911230 on ClinicalTrials.gov |
What this trial studies
This pilot study explores the effectiveness of advanced diffusion-weighted MRI (ADW-MRI) in distinguishing between true tumor progression and pseudoprogression in patients diagnosed with glioblastoma or brain metastases. The study will utilize conventional MRI alongside ADW-MRI when there is suspicion of tumor recurrence, particularly in cases where surgical resection may be necessary. Histopathological findings from resected tissue will be correlated with ADW-MRI results to assess the accuracy of this imaging technique. The primary goal is to evaluate the feasibility of this approach and analyze the relationship between imaging features and tissue characteristics.
Who should consider this trial
Good fit: Ideal candidates are patients with confirmed glioblastoma or brain metastasis who show signs of suspected tumor progression on standard MRI and are eligible for elective surgical resection.
Not a fit: Patients who are in a life-threatening condition, require emergency surgery, or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and treatment decisions for patients with glioblastoma and brain metastases.
How similar studies have performed: While advanced imaging techniques have been explored in other contexts, this specific application of ADW-MRI for differentiating tumor recurrence from pseudoprogression is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection. * Able to give informed consent Exclusion Criteria: * Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy) * Patients in a life-threatening condition * Patients in need of emergent surgery * Histopathological analyses of insufficient quality * Unable to give informed consent * Age \<18 Years
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Dominik Cordier, PD Dr. med. — University Hospital, Basel, Switzerland
- Study coordinator: Dominik Cordier, PD Dr. med.
- Email: dominik.cordier@usb.ch
- Phone: +41 61 26 56 42
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.